Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults. The American Heart Association's 2026 Heart Disease and Stroke Statistics Update reports that up to 13% of older adults hospitalized with heart failure with preserved ejection fraction may have ATTR‑CM, underscoring substantial opportunities to improve diagnosis in routine clinical care.
The American Heart Association, a relentless force changing the future of health for everyone, everywhere, has launched a multicenter cluster randomized trial to evaluate whether a structured, provider-focused evidence-based educational intervention can improve diagnostic testing and confirmed diagnosis of ATTR‑CM among patients hospitalized with heart failure.